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Abstract
Here we describe a novel conditional mouse lung tumor model for investigation of the pathogenesis of human
lung cancer. On the basis of the frequent involvement of the Ras-RAF-MEK-ERK signaling pathway in human
non–small cell lung carcinoma (NSCLC), we have explored the target cell availability, reversibility, and cell type
specificity of transformation by oncogenic C-RAF. Targeting expression to alveolar type II cells or to Clara cells,
the two likely precursors of human NSCLC, revealed differential tumorigenicity between these cells. Whereas ex-
pression of oncogenic C-RAF in alveolar type II cells readily induced multifocal macroscopic lung tumors indepen-
dent of the developmental state, few tumors with type II pneumocytes features and incomplete penetrance were
found when targeted to Clara cells. Induced tumors did not progress and were strictly dependent on the initiating
oncogene. Deinduction of mice resulted in tumor regression due to autophagy rather than apoptosis. Induction of
autophagic cell death in regressing lung tumors suggests the use of autophagy enhancers as a treatment choice
for patients with NSCLC.
Neoplasia (2011) 13, 1005–1018
Introduction
Non–small cell lung carcinoma (NSCLC) is the most prevalent type
of lung cancer and is responsible for most cancer-related deaths
worldwide [1]. Genetic analysis of human NSCLC has highlighted
the mitogenic cascade Ras-RAF-MEK-ERK as a frequent target of
mutagenesis [1,2]. In contrast to K-RAS mutations that are detected
frequently in human lung adenocarcinomas [3], activating mutations
in RAF genes are not common and are only observed in the B-RAF
gene at low frequency [4,5]. Despite lack of activating mutations, over-
expression of C-RAF was found in most human pulmonary adeno-
carcinomas [6]. Moreover, C-RAF but not B-RAF has recently been
shown to be the RAF family member of serine/threonine protein
kinase that is essential for K-ras oncogene-driven NSCLC [7]. By
now, many of the mitogen-activated protein kinase (MAPK) pathway
oncogenes have been examined in mouse models for human NSCLC,
which include spontaneous and conditional expression strategies
demonstrating a close genetic and histopathogenic relationship [8].
With respect to the cell of origin of NSCLC, a considerable body of
data indicated that oncogenic K-Ras generated invariably tumors
of type II cell lineage irrespective of whether the expression was tar-
geted to Clara and/or to alveolar type II cells [8]. Whether the
tumor-initiating cells also include bronchiolar Clara cells that trans-
differentiate to alveolar type II cells or include progenitors of these cells
has yet to be elucidated [8].
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C-RAF fusion transcripts that lost the RAS-binding domain were
found in human prostate, melanoma, and liver cancer, suggest-
ing genomic rearrangement rather than mutation as a mechanism
of C-RAF gene activation in a subset of solid tumors [9]. Previ-
ously, we have shown that constitutive expression of C-RAF BxB,
an N-terminal deleted form of C-RAF that lacks RAS-binding do-
main, or wild-type C-RAF under the control of SP-C promoter yields
thousands of adenomas that were well differentiated, poorly vascular-
ized, and did not progress to metastasis [10,11]. However, there were
several questions that could not be answered with these constitutive
models. For example, what is the target cell availability in adult versus
embryonic lung? Is tumor induction reversible, and if so, by what
mechanisms do the tumors regress? How does the range of transfor-
mation sensitive target cells compare between the oncogenic C-RAF
and K-ras? To address these critical questions, we have engineered a
novel conditional transgenic mouse line for further investigating the
pathogenesis of human NSCLC. Our findings demonstrate that the
targeted expression of transgenic C-RAF to alveolar type II cells using
SP-C rtTA mice led to the development of a limited number of
macroscopic lung tumors that did not progress to invasive and meta-
static malignancy. Moreover, embryonic or adult expression of onco-
genic C-RAF did not alter the number and the quality of the lung
tumors indicating the presence of transformation sensitive type II cells
in the postnatal lung. Curiously, the expression of oncogenic C-RAF
in Clara cells using CCSP rtTA mice failed to induce lung neoplasias in
most mice, indicating differences in the susceptibility of lung epi-
thelial cells to oncogenic insults. Importantly, tumor maintenance
was strictly dependent on the continuous expression of the initiat-
ing oncogene as discontinuing transgene expression by withdrawal of
doxycycline (DOX) resulted in the regression of adenomas. In contrast
to reversible K -rasG12D or B-RAFV600E lung tumor models [12,13],
the mechanism of regression was not associated with apoptosis but in-
volved autophagy. To our knowledge, this is the first in vivo evidence
to support autophagy as an important cell death pathway in a malig-
nant tissue. These findings are relevant for clinical studies that are
aiming to use autophagy enhancers or C-RAF inhibitors as anticancer
agents in NSCLC patients.
Materials and Methods
Generation of Transgenic Mice
All animal studies were approved by the Bavarian State authorities
for animal experimentation. Mice were housed under barrier con-
ditions in air-filtered, temperature-controlled units with a 12-hour
light-dark cycle with free access to food and water. To generate mice
conditionally expressing C-RAF BxB [10], pcDNA3 plasmid harbor-
ing ha-tagged oncogenic C-RAF, hereafter C-RAF ha-BxB, was di-
gested with HindIII and XbaI and cloned into pTS4 vector. The
resulting pTS4-C-RAF ha-BxB plasmid was subsequently cut with
SmaI and XbaI to clone a 1.3-kb C-RAF ha-BxB fragment into
pBI5 vector (containing a tet operator) using PvuII (compatible with
SmaI site) and XbaI sites. The final PBI5 C-RAF ha-BxB plasmid was
cut with AseI to remove the vector backbone, and the Tet-O C-RAF
ha-BxB fragment (6.0 kb) was isolated by gel electrophoresis and in-
jected into the pronucleus of fertilized mouse eggs. We generated
eight potential founders, and five of them showed germ line trans-
mission after polymerase chain reaction (PCR) genotyping. All posi-
tive founders were mated with either SP-C rtTA or CCSP rtTA [14]
transgenic activator lines to obtain double transgenic progeny. These
compound mice were induced with DOX (Sigma, Munich, Germany)
containing food (500 mg/kg body weight; Ssniff, Soest, Germany) for
different periods and analyzed for the phenotypic occurrence of lung
pathologic abnormality. For embryonic induction, DOX was adminis-
tered to dams from E0.5 onward. All mice were kept on FVB/n back-
ground. K-rasLA2 mice were obtained from the Jackson Laboratory (Bar
Harbor, ME) [37].
Genotyping
DNA was extracted from mouse tails and genotyping was performed
by PCR. To identify Tet-O C-RAF ha-BxB mice, TETO (5′-GCA
GAG CTC GTT TAG TGA ACC) and BxB (5′-ACA TCT CCG
TGC CAT TTA CCC) primers were used. Amplification of the
PCR product for Tet-O C-RAF ha-BxB was performed as follows:
denaturation at 94°C for 2 minutes followed by 37 cycles at 94°C
for 15 seconds, annealing at 66°C for 30 seconds and 72°C for 1 min-
ute, followed by a 5-minute extension at 72°C. Genotyping of SP-C
rtTA and CCSP rtTA transgenic mice was previously described [14].
RNA Isolation and Reverse Transcription–PCR Analysis
Total RNA was isolated from whole lungs of mice using TRIzol
(Invitrogen, Darmstadt, Germany) reagent. Samples were treated with
RNase-free DNAse I before the preparation of complementary DNA
(cDNA) using random hexamer primers provided by the First-Strand
cDNA Synthesis Kit (Fermentas, Sankt Leon-Rot, Germany). Control
reactions were run using Taq polymerase without reverse transcription
(RT) enzyme. PCR conditions for amplification of C-RAF BxB were
as follows: denaturation at 94°C for 3 minutes followed by 28 cycles at
94°C for 15 seconds, annealing at 56°C for 30 seconds and 72°C for
30 seconds, followed by a 10-minute extension at 72°C. To identify
C-RAF BxB, 5′-TGGGCCGAGGAT ATG CCTCCC and 5′-CAA
GGA TGGCTC GGA AGCGC primers were used. β-Actin was used
to check the quality of the RNA extraction and RT-PCR. The primers
and condition for β-actin have been previously described [11]. PCR
products were resolved on a 1.5% agarose gel. Real-time RT-PCR
was performed using the DyNAmo HS SYBR Green qPCR Kit (Finn-
zymes, Schwerte, Germany) in a Roto-Gene 2000 detection system
(Corbett Research, Hilden, Germany). RNA of hypoxanthine phos-
phoribosyltransferase 1 (HPRT) was used as a standard control. Anti-
sense primers for transgenic (h) C-RAF, endogenous (m) C-RAF, and
their common sense oligo (hm) were as follows: h, 5′-ACATGTGT-
TCTGCCTCTGGA-3′; m, 5′-ATGCATTCTGCCCCCAAGGA;
hm, 5′-TTTCCCCAGATCCTGTCTTCCAT-3′.
Immunoblot Analysis
For protein analysis of lung samples, mice were killed and their
macroscopic lung tumors were collected in tubes containing ice-cold
RIPA buffer with protease inhibitor cocktail. Lungs were homog-
enized for 30 seconds using an ultraturax homogenizer in a cold
environment. The homogenates were centrifuged at 11,000 rpm
for 10 minutes. After centrifugation, supernatants from samples were
analyzed for protein concentration by NanoDrop ND-1000 (Thermo
Fisher Scientific, Erlangen, Germany). The remaining extracts were
mixed with 4× Laemmli loading buffer heated to 95°C for 5 minutes
and either stored at −20°C or resolved by SDS-PAGE and transferred to
nitrocellulose membranes. After blocking for an hour in PBS (0.05%
Tween, 5% powdered skimmed milk) blots were incubated overnight
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with the following primary antibodies: anti-ha antibody (1:500, clone
3F10; Roche, Mannheim, Germany), LC3 (1:250, clone RB7481;
Abgent, Surrey, United Kingdom), mammalian kinase target of rapa-
mycin (mTOR, 1:1000, L27D4; Cell Signaling, Frankfurt, Germany),
phospho-mTOR (1:1000, Ser2481; Cell Signaling), Raptor (1:1000,
24C12; Cell Signaling), Rictor (1:1000; Cell Signaling), AMPKα
(1:1000, F6; Cell Signaling), phospho-AMPKα (Thr172) (1:1000,
40H9; Cell Signaling), p70S6K (1:1000, 49D7; Cell Signaling), phospho-
p70S6K (Thr389) (1:1000, 1A5; Cell Signaling), Akt (1:1000, 9272;
Cell Signaling), phospho-Akt (Ser473) (1:1000, 193H12; Cell Signal-
ing), Bcl-2 (1:1000, 2876; Cell Signaling), Beclin 1 (1:2500, NB500-
249; Novus Biological, Cambridge, United Kingdom), p16 (1:500,
sc-1661; Santa Cruz, Offenbach, Germany), p21 (1:500, sc-6246;
Santa Cruz), p53 (1:500, sc-126; Santa Cruz), HP-1γ (1:500, clone
42s2; Millipore, Schwalbach, Germany), cyclin D2 (1:500, sc-181;
Santa Cruz), cleaved caspase 3 (1:1000, D175; Cell Signaling), PARP
(1:1000, 46D11; Cell Signaling), and β-actin (1:5000, I-19; Santa
Cruz). After three washes with 1× Tris-buffered saline with 1% Tween
20 buffer, the membranes were incubated with corresponding anti-IgG
peroxidase–coupled secondary antibodies (GE Healthcare, Freiburg,
Germany) for 60 minutes and visualized with an ECL detection kit.
Histopathology and Immunostaining
Tissues were fixed in 4% buffered formalin for 24 hours and
then transferred to 70% ethanol before embedding in paraffin. Six-
micrometer-thickmouse tissue sectionswere cut fromparaffin-embedded
blocks, placed on glass slides. The cut slides were deparaffinized, rehy-
drated in a graded series of alcohol, and haematoxylin-eosin (H&E)
stained using standard procedures. For immunohistochemistry, sec-
tions were deparaffinized and rehydrated. For antigen retrieval, sec-
tions were incubated in 10 mM citrate buffer for 10 to 20 minutes
using microwave irradiation. Endogenous peroxidase activity was
quenched with methanol or PBS containing 1% to 3% H2O2. Non-
specific binding was blocked with 5% of serum with 0.2% Triton
X-100 for 1 hour. After blocking, sections were incubated with pri-
mary antibodies overnight at 4°C. Primary antibodies against the
following proteins were used: aquaporin 5 (AQP-005; Alomone Labs,
Jerusalem, Israel) at 1:1000, CCSP (sc-9772; Santa Cruz) at 1:2500,
pan-Cytokeratin (Z0622; Dako, Hamburg, Germany) at 1:500, Ki67
(MM1; Vector Laboratories, Lörrach, Germany) at 1:50, pro–SP-C
(gift from Jeffrey A.Whitsett), TTF-1 (M3575;Dako) at 1:100, vimen-
tin (C-20; Santa Cruz) at 1:200, E-cadherin (clone ECCD2; Zymed
Laboratories, Darmstadt, Germany) at 1:250, Pecam-1 (clone MEC
13.3; BD Pharmingen, Heidelberg, Germany) at 1:100, F4/80
(ab6640; Abcam, Cambridge, United Kingdom) at 1:100, phospho-
p44/p42 MAPK Thr202/Tyr204 (20G11; Cell Signaling) at 1:1000,
Raf-1 (E-10; Santa Cruz) at 1:400, ha-tag (3F10; Roche) at 1:200,
active caspase-3 (5A1E; Cell Signaling) at 1:200, LC3 (clone RB7481;
Abgent) at 1:100, phospho-mTOR (2448, 49F9; Cell Signaling) at
1:200, p53 (CM5; Vector Laboratories) at 1:200, CD3 (ab5690;
Abcam) at 1:250, p16 (sc-1661; Santa Cruz) at 1:50, p21 (sc-6246;
Santa Cruz) at 1:200, and HP-1γ (clone 42s2;Millipore) at 1:200. After
primary antibody incubation, sections were incubated with cor-
responding biotinylated secondary antibodies (Dako Cytomation,
Hamburg, Germany) at a 1:200 dilution for 60 minutes at room tem-
perature. ABC reagent was applied (Vectastain Elite ABX Kit; Vector
Laboratories) and developed in diaminobenzidine (DAB). Sections were
then counterstained with hematoxylin and mounted after dehydration.
Phospho–p44/p42 MAPK staining was essentially carried out as the
others except that Tris-buffered saline with 1% Tween 20 was used in-
stead of PBS. For immunofluorescence staining, the following secondary
antibodies (all obtained from Jackson ImmunoResearch Laboratories, at
1:200 dilutions) were used: donkey anti-mouse Cy3, donkey anti-mouse
Cy5, donkey anti-goat Cy5, donkey anti-goat Cy3, donkey anti-rabbit
Cy3, donkey anti-rabbit Cy5, donkey anti-rabbit Alexa 488, donkey
anti-rat Cy3, and donkey anti-rat Cy5. Masson trichrome staining was
carried out according to Sigma-Aldrich’s instruction for trichrome stain
(Masson) kit (Sigma; cat. no. HT15), which stains nuclei in black; cyto-
plasm, muscle, and erythrocytes in red, and bone/collagen in blue. To
quantify the multiplicity of LC3+ foci/tumors, we counted the number
of LC3-positive cells per five randomly selected tumor areas for each
tumor. At least five tumors were counted for each lung tumor section.
We used three mice for each time point. Apoptotic cells were identified
using the Dead End Fluorometric TUNEL-Kit (Promega, Mannheim,
Germany) according to the manufacturer’s instructions. Scoring for
Ki67- or TUNEL-positive cells was carried out by counting the number
of positive nuclei per field in 10 randomly chosen tumor regions at 40×
magnification. Approximately 500 to 1500 nuclei were screened per each
field. For each condition, all data from three to four separate mice were
pooled to obtain final cell numbers. Further evaluation of apoptosis was
carried out by analyzing internucleosomal cleavage of DNA. For ge-
nomicDNA isolation, lung tumors were digested usingGentra Puregene
Tissue Kit (158622; Qiagen, Hilden, Germany) according to the man-
ufacturer’s instructions. Genomic DNA isolated from mouse MLE-15
NSCLC cells (using Gentra Puregene Cell Kit (158388; Qiagen) that
were treated either with cycloheximide (5 μg/ml, C4859; Sigma) or with
doxorubicin hydrochloride (2 μg/ml; Fisher Bioreagents, Schwerte,
Germany) for 24 hours were used as positive controls. For the analysis
of H&E staining and immunohistochemistry, we used Zeiss Axio Scope.
A1 or Zeiss Discovery V8 Streo microscopes (Carl Zeiss MicroImaging
GmbH, Göttingen, Germany) integrated with AxioCam ICc3 camera
(Spectra Service, Ontario, NY). Images were acquired using AxioVision
Rel. 4.7 software provided by Zeiss. Negative controls included the omis-
sion of the primary antibody. Macroscopic lung lesions were counted
before fixation.
Statistical Analyses
Differences among the groups were compared with Student’s
t test using GraphPad Prism 5 software (GraphPad Software, Inc,
San Diego, CA). Results are presented as means ± SEM. All P values
were 2-tailed. Survival and tumor incidence were analyzed by the log-
rank test. P < .05 was considered statistically significant.
Results
Generation of Mice with a Conditional C-RAF Oncogene
To generate mice in which we could regulate the expression of
oncogenic C-RAF (C-RAF BxB) in respiratory epithelial cells, the
tet-regulated construct (Tet-O C-RAF ha-BxB) was prepared as de-
scribed in the Materials and Methods section. After screening of
genomic DNA from pups, we have obtained six transgenic mouse
founders that showed positive germ line transmission for the insert.
To facilitate detection of transgene expression, an ha-tag was added
to the N-terminal part of the oncogenic C-RAF (Figure 1A). Each
founder was crossed with a SP-C rtTA activator mouse line that di-
rects rtTA expression into alveolar type II cells [14] to obtain double-
transgenic (DTR) mice. The resulting DTR mice (hereafter referred
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Figure 1. Inducible expression of oncogenic C-RAF in alveolar type II cells leads to macroscopic lung tumor development. (A) Schematic
representation of the constructs for conditional expression of oncogenic C-RAF in type II pneumocytes. (B) RT-PCR analysis of total lung
samples prepared from DTRS mice demonstrates oncogenic C-RAF transcript only in induced mice. (C) Triple immunofluorescence
staining of lung sections from DTRS mice for the indicated antibodies showing oncogenic C-RAF expression (arrows) in a fraction of
alveolar type II cells after DOX treatment. (D) Photographs of representative lungs with multiple macroscopic pulmonary nodules (ar-
rows). (E) Quantitation of lung tumors in embryonic and adult induced DTRS mice. Error bars are SEM from eight different mice for each
category. NS indicates not significant. *Statistically significant (P < .05).
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to as DTRS where “S” stands for SP-C rtTA) were then placed on a
continuous DOX diet at 5 weeks of age for a period of 4 to 6 months
and killed for pathologic examination. Histologic examination of
lung sections from induced DTRS mice showed lung tumors in
two (founder numbers; 3579 and 2393) of the six founders (Fig-
ure W1). On the basis of larger tumor size and longer latency (2 vs
4-5 months), a feature of human NSCLC, we first selected founder
number 2393 for the subsequent experiments (Figure W1). To deter-
mine the transgene expression, 5-week-old DTRS mice were DOX
treated for 1 week and analyzed by semiquantitative RT-PCR and
by immunofluorescence staining. RT-PCR analysis of total lungs from
induced and control DTRS mice showed oncogenic C-RAF expression
only in induced mice demonstrating tight regulation of transgene ex-
pression (Figure 1B). Consistent with the site of expression of the
human SP-C promoter [15], oncogenic C-RAF expression judged by
ha-tag staining was found in a fraction of alveolar type II cells but not
in bronchiolar Clara cells of the induced DTRS mice (Figure 1C ).
Expression of Oncogenic C-RAF in Alveolar Type II Cells
Elicits Multiple Macroscopic Lung Tumors
In contrast to our previous constitutive RAF transgenic mouse
model (SP-C C-RAF BxB), in which thousands of microscopic ade-
nomas were formed [10], adult induction of oncogenic C-RAF in
type II pneumocytes generated visible macroscopic lung tumors al-
beit at low number and longer latency (Figure 1D). To test whether
the discrepancy in the observed tumor incidence between the two
strains was associated with the time course of induction, we next pro-
longed DOX treatment of adult DTRS mice to 9 and 15 months,
respectively. Interestingly, incidence and size of the tumors increased
with continued exposure to DOX (Figure 1D). Despite higher tumor
burden in long-term-induced adult DTRS mice, the number of pul-
monary tumors was still low in comparison with the constitutive model.
We therefore had to consider that the number of transformation-
sensitive cells targeted by the oncogenic C-RAF differs during and
after lung development. To test this hypothesis, DTRS mice were
either prenatally or postnatally exposed to sustained DOX induction
during a 9-month period. To our surprise, quality and multiplicity of
macroscopic lung tumors did not differ between embryonic and adult
induction (Figure 1E). Taken together, these data show that oncogenic
C-RAF is a potent initiator of lung tumors originating in alveolar type II
cells and the number of target cells available for transformation is
independent of developmental age.
Lack of Tumor Progression in Macroscopic Lung Tumors
With respect to histopathology, induced pulmonary tumors were
alveolocentric and composed of a monomorphous population of cells
arranged in a ribbon pattern with no nuclear pleomorphism (Fig-
ure 2A). Tumors contain minimal stroma consisting of collagen
fibers (Figure W2) and displayed lepidic growth along alveolar septa
without tissue destruction (Figure 2A). Similar to the constitutive
C-RAF transgenic mouse model, we did not detect focal hyperpla-
sia at all ages analyzed. Consistent with oncogenic C-RAF expres-
sion judged by ha-tag staining, tumor cells showed strong C-RAF
and nuclear phospho-ERK1/2 expression (Figure 2B). Similar to
B-RAFV600E– or K-rasV12–driven murine lung tumors where tumor
cells progressively showed diminished proliferation and gained the
features of senescence [16–18], tumor cells fueled by oncogenic
C-RAF showed reduced nuclear staining of Ki67 and heterogeneous
expression of HP-1γ, p21WAF1, and p16INK4a (Figure W3, A and
B). Notably, we often found increased active macrophage accumula-
tions around the tumors but not intratumorally (Figure W4A). In
contrast to macrophages, T cells were frequently detected in the
tumors (Figure W4B).
To ascertain the cell type and differentiation status of the tumors,
immunohistochemistry was performed using antibodies against Clara
cell antigen (CCSP) and the surfactant protein C (SP-C), commonly
used markers that distinguish between Clara cells and alveolar type II
cells, respectively. All of the lung tumors were found to be positive for
pro–SP-C and negative for CCSP, implicating alveolar type II cells as
the origin of these lesions (Figure W5). We detected homogenous
nuclear TTF-1 expression as well as heterogeneous expression of aqua-
porin 5 in tumors (Figure W5). Consistent with the lack of invasive
edges, tumor cells did not show evidence for epithelial-mesenchymal
transition as judged from the sustained expression of epithelial markers
such as Pan-cytokeratin, E-cadherin (Figure W6A), and negative ex-
pression of the mesenchymal marker Vimentin (Figure W6B). In
agreement with our previous results [11], pulmonary tumors initiated
by adult expression of oncogenic C-RAF were generally poorly vas-
cularized and showed low density of blood vessels only at the tumor
periphery (Figure W7A). Lack of angiogenic induction was also main-
tained in tumor nodules larger than 1.5 mm diameter (Figure W7B).
Despite their benign characteristics, we went on to examine whether
tumors with this striking macroscopic appearance gave rise to metas-
tasis. Intensive histopathologic inspection of large cohorts of mice did
not reveal any micrometastases or macrometastases in the regional
lymph nodes or in distant organs (Figure W8). On the basis of all
these histologic criteria, we concluded that induced tumors driven
by oncogenic C-RAF are well differentiated and do not progress to
malignancy, thus classifying them as adenomas. These data also clearly
implicate that tumor size is not necessarily a criterion for malignancy.
Clara Cell–Targeted Expression of Oncogenic C-RAF Results
in Rare Lung Tumor Formation
We next wanted to evaluate oncogenic C-RAF for its ability to trans-
form Clara cells. To meet this goal, Tet-O C-RAF ha-BxB single-
transgenic mice were bred with the CCSP rtTA inducer line to obtain
DTR mice (hereafter referred to as DTRC where “C” stands for CCSP
rtTA) (Figure W9A). Similar to DTRS mice, we readily detected trans-
gene messenger RNA (mRNA) expression in induced mice (Fig-
ure W9B). Consistent with the sites of expression of the rat CCSP
promoter [19–21], expression of ha-tag was detected both in Clara cells
and in the alveoli (Figure W9C). To determine tumorigenic effects of
oncogenic C-RAF in Clara cells, adult DTRC mice were kept under
continuous DOX for different time points. In contrast to DTRS mice,
pathologic inspection of large cohorts of DTRC mice during long-term
DOX stimulation did not reveal visible lung lesions in most mice even
when we prolonged the induction for 18 months (Figure 3, A and B).
Lack of pulmonary nodules in DTRC mice was not a function of the
maturity of Clara cells as embryonic induction also gave rise to similar
results (Figure 3B). Moreover, tumor-bearing DTRS mice died at the
expected rate [22], whereas DTRC mice survived for the entire induc-
tion period (Figure 3A). Histologic examination of lung sections from
induced DTRC mice showed the absence not only of pulmonary tu-
mors but also of Clara cell hyperplasia (Figure 3C ). Only in a minor-
ity (3/32) of the induced DTRC mice between the ages of 12 and
18 months, we found a low number of macroscopic lung tumors
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(Figure 3D). These tumors were indistinguishable from those found in
DTRS mice in their macroscopic appearance and histology (Figure 3D).
As in the case of DTRS mice, lung tumors were not bronchiolocentric
and found to be positive for pro–SP-C and negative for CCSP, sug-
gesting that these lesions arose from alveolar type II cells or their pre-
cursors (Figure 3D).
To address whether differential tumorigenicity between the DTRS
and DTRC mice related to the level of transgene expression, we com-
pared mRNA levels by real-time RT-PCR. We found similar levels
of oncogenic C-RAF expression between the mice groups (Fig-
ure W9D). As such, comparison of transgene mRNA levels to endog-
enous expression of C-RAF gave rise to identical results between
DTRS and DTRC mice (Figure W9E ). Failure to induce lung neo-
plasia in most of the induced DTRC mice might be related to the
choice of the founder line (founder 2393) because there are exam-
ples of idiosyncratic properties of single founder strain lines. We
therefore established similar mating using another mouse founder
line (founder 3579) that responds to oncogenic C-RAF expression
with lung tumor formation with relative early latency (Figure W1).
Toward this aim, DTR mice both from SP-C rtTA (referred as
DTRS2 where “2” indicates the second founder) and CCSP rtTA (re-
ferred as DTRC2) crosses were induced with DOX for 3.5 months
Figure 2. Histopathologic analysis of lung tumors induced by oncogenic C-RAF. (A and B) Lung sections from 15-month-induced DTRS
mice were stained with the indicated markers. Pictures in the right-hand panel are the higher-magnification views of the boxed areas
(yellow) shown in left panels. Hematoxylin (blue) was used as a counterstain.
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of period. As expected, examination of the lung slides from DTRS2
mice showed multiple pulmonary adenomas (Figure W10, A and B).
Consistent with their transgene origin, all the lung tumors expressed
ha-tag and stained positive for pro–SP-C but not for Clara cell marker
CCSP, attesting to alveolar type II cell origin (Figure W10C). Simi-
lar to DTRC mice, DTRC2 mice also failed to develop lung tumors
and showed generally normal bronchiolar structures (Figure W10, B
and D). Distinct from DTRC mice, we found bronchiolar hyper-
plasias in a minor fraction (1%-2%) of the induced DTRC2 mice
(Figure W11A). Such hyperplastic lesions were never found in control
Figure 3. Differential tumorigenicity between type II pneumocytes and Clara cells targeted by active C-RAF. (A) Kaplan-Meier curves for
lung tumor incidence and survival with the indicated genotypes. Animal numbers are as indicated. DOX-treated DTRS mice display statis-
tically significant (log-rank analysis) tumor penetrance associated with reduced life span compared with their counterparts. (B) Photographs
of lungs and their representative pictures of H&E-stained sections from DTRC mice showing lack of lung tumors after long-term
(13 months) DOX induction compared with age-matched DTRS mice. (C) Representative H&E-stained lung sections from control and
induced (13 months) DTRC mice showing normal bronchiolar morphology. (D) Photograph of lung isolated from a 13-month-induced DTRC
mouse showing pulmonary tumors (red arrow) and their immunohistochemical characterization with the indicated markers. Br indicates
bronchiole; T, tumor.
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DTRC2 mice. The rare bronchiolar hyperplasias arising within the ter-
minal bronchioles displayed papillary excrescences (Figure W11B).
Unexpectedly, this hyperplastic epithelium stained negative for CCSP
but positive for pro–SP-C, suggesting a transdifferentiation event
toward alveolar lineage (Figure W11B). Lack of lung tumors derived
from bronchiolar Clara cells was not due to the induction of prema-
ture senescence because we did not observe p19ARF or p16INK4a ex-
pression in ha-tag–expressing Clara cells of the DTRC mice (data
not shown). Taken together, these results indicate that lung epithelial
cells targeted by the rat CCSP promoter are strongly refractory to
oncogenic C-RAF–driven neoplastic transformation.
Oncogenic C-RAF Is Essential for Tumor Maintenance
To assess the dependence of lung tumors on oncogenic C-RAF for
survival and continued growth, tumor-bearing DTRS mice (induced
for 8 months) were taken off the DOX diet for 1 month. Macroscopic
inspection of whole lungs from deinduced mice showed strong reduc-
tion in tumor burden with few persistent lesions remaining after DOX
withdrawal (Figure 4A). To assess the early effects of DOX withdrawal
on tumor phenotype, DOX was removed from mice carrying estab-
lished tumors at different time points. After 3 days of DOX with-
drawal, we did not observe any histologic alterations in the tumor
cell morphology in comparison with the control cells (Figure 4B).
However, after 1 week, we detected a significant reduction in staining
intensity (H&E) in central tumor sections, which was even more pro-
nounced after 2 weeks of DOX removal while maintaining tumor
structure (Figure 4B). The pale tumor cells disappeared gradually
and were replaced by normal-looking pulmonary tissue (Figure 4B).
Staining of lung sections with an ha-tag antibody paralleled the his-
tologic observations and showed diminished transgene expression
gradually after DOX withdrawal (Figure 4C ). Notably, both colla-
gen fibers and T cells that are present in the stroma of control (ON
DOX) tumors (Figures W2A and W4B) completely disappeared after
discontinuing transgene expression (Figures W12 and W13). Inter-
estingly, we detected a dramatic loss of pro–SP-C expression in the
regressing lung tumors indicating a dedifferentiation process (Fig-
ure W14, A and B). These data indicate that maintenance of lung
tumors and their stromal components requires continuous expression
of oncogenic C-RAF.
To address the mechanism of tumor regression, we first focused on
the involvement of cell cycle arrest in lung tumors removed from the
DOX. We found that the shutdown of oncogenic C-RAF expression
from the induced lung tumors caused reduced cell proliferation as
evident by a substantial decrease of Ki67-positive cells (Figure W15,
A and B). Reduction of cyclin D2 levels in regressing lung tumor
lysates supported this finding (Figure W15C ). Another cell autono-
mous mechanism that restricts tumor growth is oncogene-induced
senescence, an irreversible form of growth arrest [17,23]. Whereas
inactivation of the senescence program allows progression of benign
preneoplastic lesions to full-blown malignant cancers [24–27], its
reactivation in murine tumors is associated with tumor regression
[28,29]. To determine the state of senescence in tumors removed
from DOX, we analyzed a panel of senescence-associated markers
that we have found to be expressed in oncogenic C-RAF-induced
lung tumors (Figure W3B). Similar to oncogenic K-ras–induced lung
tumors, staining with antibodies against p21Waf1, p16INK4a, and
HP-1γ revealed positive cells in tumors, whereas tumors removed from
DOX were essentially negative (Figures W16A and W4B). Immuno-
blot analysis of lung tumor lysates confirmed the reduced expression
of HP-1γ but not the p21Waf1 and p16INK4a expressions that were
absent in all samples presumably due to the low expression of these
proteins (Figure W16B). In contrast to these senescence markers,
p53 protein levels were found to be elevated during the tumor re-
gression (Figure W16, A and B). Interestingly, the nuclear p53 ex-
pression that we detected in a small fraction of induced tumor cells
switched to marked cytoplasmic staining during the tumor regression
(Figure W16A).
Although cell cycle arrest was found to be part of tumor regression
in many instances, complete elimination of tumors requires a cell
death–related mechanism because cell cycle arrest will only induce
a sustained tumor state. We therefore performed active (cleaved)
caspase 3 immunostaining on lung tumor slides from DTRS mice
removed from the inducer. Surprisingly, we did not observe any posi-
tive cell after DOX withdrawal at any time point, indicating that
tumors were not regressing through an apoptotic mechanism (Fig-
ure 4D). Similar results were obtained with TUNEL (Figure W17)
or DNA fragmentation (Figure W18A) assays as well as by immuno-
blot analysis of tumor lysates with antibodies against cleaved caspase 3
or PARP cleavage (Figure W18B). Apart from apoptosis (type 1 cell
death), autophagic (type 2 or macroautophagic) cell death, a process
of self-degradation of cellular components, has often been proposed
to be an alternative mechanism of programmed cell death. In contrast
to apoptosis, autophagic cell death is caspase independent and does
not involve classic DNA laddering. To address this possibility, we
performed immunohistochemistry on lung tumor sections using
microtubule-associated protein 1 light chain 3 (LC3) antibody that
detects autophagosome formation [30]. In contrast to the control
tumor sections, we detected very strong LC3 staining in all regressing
lung tumors 1 or 2 weeks after DOX withdrawal (Figure 5, A and
B). Punctuate pattern of LC3 staining rather than a cytosolic diffused
pattern suggest the formation of autophagosomes typically formed
during autophagy induction (Figure 5, A and C). Notably, consistent
with lower autophagic capacity of cancer cell lines than their normal
counterparts [31], we detected marked and diffused LC3 staining in
nontumor region of the induced lung tumors (Figure W19). During
autophagy, the LC3 cytosolic form (LC3-I) undergoes proteolytic
cleavage and lipidation to generate the autophagic vacuole-bound
and lipid-conjugated form (LC3-II) [32]. We therefore analyzed in-
duction of LC3-I and its conversion to LC3-II, both being hallmarks
of autophagy, in lung tumor samples by immunoblot analysis before
and after DOX withdrawal. Consistent with strong LC3 expression in
regressing tumors (Figure 5A), we found significantly increased LC3-I
and LC3-II levels after deinduction indicating autophagy (Figure 5D).
Analysis of other autophagy-related proteins such as Bcl-2 and Bcl-2–
interacting protein, Beclin 1, did not show remarkable differences be-
tween the treatment groups (Figure 5D). To investigate the underlying
mechanism of autophagy induction in our regressing lung tumors, we
focused on mTOR signaling because this pathway was previously
shown to play a role in autophagy suppression in several systems
[33–35]. Toward this aim, components of the mTOR signaling were
assessed in regressing lung tumor lysates by Western blot analysis. We
found significantly decreased or no expression in all of the mTOR
signaling–related markers that we have tested, except Raptor that is
not expressed in all of the samples, after 1 week on removal of
DOX (Figure 6A). Similarly, screening of lung tumor sections with
phospho-specific (2448) mTOR antibody showed very strong reduc-
tion only in regressing lung tumors but not in their nonneoplastic re-
gions such as bronchioles that were shown to be positive (Figure 6B).
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Figure 4. Oncogenic C-RAF expression is essential for lung tumor maintenance. (A) Inspection and quantitation of whole lungs from
8-month-induced DTRS mice showing strong reduction in the tumor burden with few persistent nodules (arrows) after deinduction of
oncogenic C-RAF for 1 month. The difference between the mice groups is statistically significant (P < .05), n = 10. (B) Representative
examples of H&E-stained lung sections from the tumor-bearing DTRS mice illustrating regressing tumor regions (red arrows) after DOX
removal for the indicated time points. At least three mice were analyzed for each time point. (C and D) Staining of tumor-bearing lung
sections with indicated markers before and after DOX withdrawal. For active caspase 3 immunostaining, a lung tumor section from
DOX-treated SP-C rtTA/Tet-O c-Myc bitransgenic mice that we previously showed to induce apoptosis (arrowheads) [22] was used as
a positive control. Hematoxylin (blue) was used as a counterstain.
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Figure 5. Tumor regression induced by DOX withdrawal is associated with autophagy. (A and B) Staining of lung sections from DTRS
mice with LC-3 antibody before and after DOX withdrawal. Circled areas (yellow) mark LC-3–positive (brown) regions. Hematoxylin (blue)
was used as a counterstain. (B) Quantitation of LC-3 immunohistochemistry. At least 20 tumors from four mice for each time point of
DOX treatment were assessed. *Statistically significant (P < .05). (C) Immunofluorescence staining of a regressing lung tumor section
for LC-3 (green) showing a punctate staining pattern (arrows). Nuclei were counterstained with DAPI (blue). (D) Western blot analysis of
lung tumor protein lysates from DTRS mice with the indicated time points and markers.
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Inhibition of mTOR signaling and induction of autophagy judged by
decreased phosphorylation of p70S6K and increased levels of LC3, re-
spectively, in regressing lung tumor samples were associated with
decreased levels of AMPKα phosphorylation, indicating that AMPK
was not activated under these conditions (Figure W20).
Autophagy has also been associated with promotion of cell viabil-
ity in several systems [36]. In line with this prosurvival role of auto-
phagy, we observed a transient increase in phospho-Akt (Ser473)
levels in tumors from mice recently removed from the inducer (Fig-
ure 6A). Taken together, these data demonstrate that deinduction of
oncogenic C-RAF in established lung tumors triggers an autophagic cell
death rather than apoptosis that ultimately leads to tumor shrinkage.
Discussion
Susceptibility of different cell types to oncogenic insults and onco-
gene addiction are important questions in tumor biology. Here we
describe the generation and characterization of a new Tet-inducible
oncogenic C-RAF transgenic mouse model for human NSCLC that
sheds light on these questions. Our results reveal striking differences in
Figure 6. Down-regulation of mTOR signaling in regressing lung tumors. (A) Lung tumor lysates isolated at the indicated time points
were immunoblotted with the indicated markers. (B) Immunohistochemistry of lung tumor sections with phospho-mTOR (2448)–
specific antibody from the indicated DOX schedules. Arrows point out positive cells in a bronchiole (Br). Hematoxylin (blue) was used
as a counterstain.
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tumorigenicity between type II pneumocytes and bronchiolar Clara
Cells, the cell types that are commonly believed to be the putative ori-
gin of human NSCLC [8]. Importantly, the present study establishes
the first link between autophagic cell death and tumor regression.
A large body of earlier work has established that mutated compo-
nents of the mitogenic cascade such as K-ras, B-RAF, and C-RAF are
causally involved in the initiation and maintenance of lung neoplasia
in mice [10,12,13,16,37–42]. Histopathologic examination of lung
tumorigenesis in these animal models also highlighted major differ-
ences in tumor initiation, tumor numbers, tumor latency, as well as
tumor cell morphology and tumor progression. Apart from their
oncogenic actions, one possible explanation for these differences may
be the distinct target cell specificities of the applied oncogenes. To test
this hypothesis, we targeted oncogenic C-RAF expression to alveolar
type II or bronchiolar Clara cells and evaluated tumor initiation and
progression in the lung using a conditional transgenic system. The most
striking outcome of this experiment was the failure of the lung tumor
formation in most DTRC mice compared with DTRS mice. Intrigu-
ingly, rare lung tumors found in DTRC mice did not seem to arise
from Clara cells because these tumors both morphologically and histo-
pathologically were indistinguishable from those found in DTRS mice.
It is therefore likely that these peripherally located rare lung tumors
simply originated from type II cells rather than Clara cells as a result
of ectopic expression of the rat CCSP promoter in mouse lung [19–
21]. Whatever the tumor cell of origin is, the absence of lung adenomas
in most DTRC mice is in sharp contrast with the oncogenic K-rasG12C
mouse model in which multiple pulmonary tumors of type II cell
lineage were formed when targeted by either CCSP or SP-C promoters
[13]. The differential susceptibility of Clara cells or their precursor
BASCs [43] to oncogenic–K-rasG12C or –C-RAF might be related to
their MAPK activation. Expression of oncogenic K-Ras results in a
low to moderate activation of the MAPK pathway in the lung and
leads to both alveolar and bronchiolar hyperplasias preceding the bron-
chiolocentric lung tumors [38,44]. As such, expression of C-RAF levels
was found to be lower in tumors with K-Ras mutation than in those
without mutation [45]. Oncogenic C-RAF, however, hyperactivates
the MAPK pathway and predominantly forms alveolocentric tumors
in the absence of preneoplastic lesions. If oncogenic C-RAF expression
is targeted to either BASCs or Clara cells using CCSP rtTA, high
MAPK activation might induce differentiation or transdifferentiation,
respectively, toward the alveolar lineage. In this case, the CCSP pro-
moter would be turned off and oncogenic C-RAF would no longer
be expressed. Thus, transdifferentiation of Clara cells to alveolar type
II cells as previously suggested [46] might be an underlying reason
for loss of the oncogenic signal, preventing expansion of such tumor
cells. Concomitant with CCSP loss, pro–SP-C expression that we
found in bronchiolar hyperplasias from DTRC2 mice supports such a
hypothesis. However, maintenance of the CCSP expression or absence
of the bronchiolar hyperplasia in most DTRC2 mice suggests alternative
mechanisms accounting for the resistance of BASC or Clara cells to
neoplastic transformation induced by oncogenic C-RAF. Similar to
C-RAF, oncogenic B-RAF also induces high activation of the MAPK
pathway in the lung [13,16]. Interestingly, conditional expression of
oncogenic B-RAF (V600E) using CCSP rtTA transgenic mice was
shown to elicit multiple lung adenomas with alveolar type II cells fea-
tures [13]. However, the authors performed these experiments only in
the presence of Ink4A/Arf−/− background suggesting that additional
genetic hits are required for the transformation of Clara cells by onco-
genic C-RAF or B-RAF [13]. Recently, in a study of small cell lung
carcinoma (SCLC), the susceptibility of lung lineage cells to oncogenic
transformation by Trp53 and Rb1 inactivation was assessed. In this
tumor model, similar to our results, Clara cells but not alveolar type II
and neuroendocrine cells were found to be largely resistant to transfor-
mation [47] again suggesting a differential susceptibility of pulmonary
epithelial cells to oncogenic insults.
One of the advantages of the conditional system that we used is
the ability to turn off the transgene expression in established tumors
and thus determine the role of oncogenes in tumor maintenance.
Similar to other murine lung models, pulmonary tumors fueled by
oncogenic C-RAF were also oncogene addicted because removal of
transgene expression caused severe tumor regression. Earlier mouse
lung tumor models in which oncogenic K-Ras (G12D or G12C)
was conditionally expressed in pulmonary epithelial cells using CCSP
rtTA mice showed conflicting results about the mechanism of
tumor regression. Fisher et al. [12] showed that down-regulation
of K-RasG12D in established lung tumors results in tumor shrinkage
through apoptosis. In a similar bitransgenic mouse system where
oncogenic K-RasG12C is the driver for lung tumorigenesis, Floyd et al.
[42] showed that tumor regression was not occurring through apop-
tosis but rather through a mechanism alternative to apoptosis. In
accordance with lack of apoptosis in CI-1040 (PD184352) MEK
inhibitor–mediated tumor lung regression [48], we also did not detect
apoptosis in oncogenic–C-RAF–driven lung tumors after DOX with-
drawal. Tumor regression in the absence of apoptosis can also occur
through reactivation of the cellular senescence program associated with
differentiation and activation of innate immune response that targets
tumor cells [28,29]. Consistent with oncogene-induced senescence,
discontinuing oncogenic C-RAF expression from the established lung
tumors led to a strong reduction in the senescence markers, indicating
that the senescence program was not activated under this condition.
Moreover, loss of differentiation and lack of inflammatory cells in lung
tumors removed from the DOX suggest a different mechanism rather
than senescence accounting for tumor shrinkage. Our further attempts
to elucidate the mechanism of tumor clearance in our inducible system
revealed induction of autophagy after down-regulation of oncogenic
C-RAF. Apart from its role in cell death, autophagy ensures survival
in nutrient-poor conditions through lysosomal recycling of intracellular
nutrients [36]. Recent studies indicate that mTOR negatively controls
autophagy as a downstream target for AKT/PKB in response to amino
acids [49,50]. Such a negative regulation also exists in regressing lung
tumors after shut down of oncogenic C-RAF. Currently, we do not
know whether C-RAF directly regulates autophagy. Addiction of
tumor cells to high levels of MAPK signaling rather than withdrawal
of C-RAF expression may elicit cellular stress that leads to autophagy.
The tumor suppressor p53 plays a critical role in sensing genotoxic and
other stresses. Both activation and inhibition of autophagy were linked
with p53, indicating a complex relationship between autophagy and
p53 [51,52]. The mechanism by which p53 promotes autophagy
was shown to be associated with DRAM transactivation [53] or mTOR
inhibition through AMPK activation [51]. The negative regulation
of mTOR by p53 was shown to be independent of the cell cycle
regulation by p53 [51]. Elevated cytoplasmic p53 expression and
inhibition of mTOR signaling in lung tumors discontinued from
oncogenic C-RAF suggested p53/AMPK/mTOR signaling axis as an
underlying mechanism; however, we found no evidence of AMPK
activation under these conditions. The extent to which increased cyto-
plasmic p53 expression modulates autophagy induction in the present
study remains to be determined.
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In addition to RAF, oncogenic forms of RAS are also implicated in
the negative control of autophagy, through activation of class I PI3K
[54]. To check whether suppression of autophagy in C-RAF–induced
lung tumors also involves activation of PI3-kinase signaling, we com-
pared phospho-AKT (Ser473) levels, as a downstream component of
PI3-kinase signaling. We observed an interesting phenomenon that
the removal of the inducers from the already-established tumors caused
a transient elevation of phospho-AKT (Ser473) that becomes un-
detectable after prolonged DOX withdrawal. Increased phospho-
AKT (Ser473) levels in recently regressing lung tumors might have
been resulted from the initial degradation of the cell organelles, which
is then used for energy resources to enable cell survival. This obser-
vation might also be an example of dual function of autophagy in
mediating both cell survival and cell death.
In summary, our results describe a novel mouse lung tumor model
demonstrating differential tumorigenicity between pulmonary pe-
ripheral epithelial cells and providing a new tool for understanding
oncogene addiction in the context of autophagy. We expect that
these mice will be valuable in the future for the development of
new anticancer therapeutics that specifically targets the RAS/RAF/
MAPK pathways as well as in testing autophagy enhancers in the
treatment of NSCLC.
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Figure W1. Analysis of lung tumor induction in different Tet-O C-RAF ha-BxB transgenic mouse founders. Each responder founder line
was crossed with SP-C rtTA inducer line to generate double-transgenic (DTR) mice. Representative pictures of H&E-stained lung sections
from DTR mice before and after DOX administration. Blue circles indicate focal pulmonary tumors.
Figure W2. Collagen expression in oncogenic C-RAF–driven lung tumors. Masson trichrome staining of a representative lung tumor
section from a 9-month-induced DTRS mouse showing collagen expression (blue).
Figure W3. Lung tumors induced by oncogenic C-RAF are positive for the markers of senescence. (A) Ki67 staining (brown) of lung
tumor sections from induced DTRS mice showing diminished proliferation after prolonged induction. (B) Immunohistochemical analysis
of sections from K-rasLA2– or oncogenic C-RAF–induced lung tumors for the indicated antibodies. Arrows indicate positive cells for the
corresponding protein. Hematoxylin (blue) was used as a counterstain for immunohistochemistry.
Figure W4. Analysis of immune cells in oncogenic C-RAF–driven lung tumors. (A and B) Immunohistochemistry of lung tumor sections
for immune cells markers as indicated. Right panel pictures are the higher magnifications of the insets. Hematoxylin (blue) was used as a
counterstain for immunohistochemistry.
Figure W5. Assessment of lung lineage markers in induced tumors. Lung sections (fixed in formalin) from induced (12 months) DTRS
mice were immunostained with the indicated antibodies. Higher-magnification views of the boxed tumor regions are shown in the right
panels. As a counterstain, hematoxylin (blue) was used.
Figure W6. Evaluation of EMT markers in induced lung tumors from DTRS mice. (A) Immunohistochemistry for paraffin-embedded
lung sections from 15-month-induced DTRS mice with the indicated antibodies; right panel pictures are the higher-magnification views
of the boxed areas (blue). (B) Immunofluorescence costaining of lung sections with the indicated antibodies. Tumor cells were marked
by pro–SP-C (green) expression. Arrows point out rare vimentin-positive (red) cells that are negative for pro–SP-C (merge). DAPI (blue)
shows nuclei.
Figure W7. Lack of angiogenic switch induction in macroscopic pulmonary tumors fueled by oncogenic C-RAF. (A) Lung tumor sections
from 6- (top left) and 9-month- (top right) induced DTRS mice were stained with Pecam-1 antibody for evaluation of tumor vasculature.
Pictures shown at the bottom (left and right) are the higher-magnification views of the black and red boxed areas, respectively. Blue
arrows demonstrate peritumoral blood vessels. (B) Representative Pecam-1 immunohistochemistry of a tumor lung section obtained
from a long-term (17 months) DOX-treated DTRS mouse. Image on the right side represents a higher-magnification view of the area
indicated by the green box. Arrows (blue) point out peritumoral blood vessels. Hematoxylin (blue) was used for counterstaining.
Figure W8. Incidence of metastasis. Paraffin-embedded sections
of indicated organs obtained from young and old-aged cohorts of
DTRS mice were screened for regional and distant colonization of
tumor cells by immunohistochemistry using antibodies against
Pan-cytokeratin and ha-tag. LN indicates lymph node (include
mediastinal and axillary lymph nodes). Animal numbers (n) and
ages are as indicated.
Figure W9. Targeting and analysis of oncogenic C-RAF expression in bronchiolar Clara cells using CCSP rtTA mice. (A) Schematic rep-
resentation of the constructs for conditional expression of oncogenic C-RAF in Clara cell lineage. (B) RT-PCR analysis of total lung sam-
ples prepared from DTRC mice demonstrates oncogenic C-RAF (C-RAF BxB) transcript only in induced mice. The transcript of β-actin
serves as an internal control. (C) Dual immunofluorescence staining of paraffin-embedded lung sections from DTRC mice with CCSP and
ha-tag antibodies showing oncogenic C-RAF expression in bronchiolar epithelial cells (white arrows) and in a subset of alveolar epithelial
cells (yellow arrows) after DOX treatment. DAPI (blue) shows nuclei. (D and E) Real-time RT-PCR analysis of oncogenic C-RAF (hCRAF)
and its comparison to endogenous expression of C-RAF (mCRAF) between DTRS and DTRC mice. h indicates human; m, mouse. Error
bars are SEM from four different mice for each category. ns indicates not significant.
Figure W10. Comparison of lung tumor induction potential between DTRS2 and DTRC2 mice using Tet-O C-RAF ha-BxB 3579 founder
line. (A) Representative pictures of H&E-stained lung sections from control (OFF DOX) and embryonically induced (ON DOX) DTRS2 mice.
Red arrows point out pulmonary lung adenomas. (B) Quantitation of tumor load between the groups as indicated. Error bars are SEM
from six different mice for each category. (C) Staining of lung tumor sections from DTRS2 mice with the indicated markers. Hematoxylin
(blue) was used as a counterstain. (D) H&E-stained lung sections from control and induced DTRC2 mice showing the absence of pul-
monary tumors or bronchiolar hyperplasia.
Figure W11. Formation of bronchiolar hyperplasia and their transdifferentiation to alveolar lineage in induced DTRC2 mice. (A) Incidence
of bronchiolar hyperplasia. At least 450 terminal bronchioles were evaluated from lung sections of eight mice for each group. (B) Stain-
ing of lung sections from different animals carrying bronchiolar hyperplasia with the indicated markers. Red arrows points out papillary
epithelial hyperplasias.
Figure W12. Loss of collagen expression in regressing lung tumors.
Masson trichrome staining of lung tumor sections from DTRS mice
showing strong reduction in collagen expression (blue) after DOX
removal at the indicated time points.
Figure W13. Absence of T cells in regressing lung tumors. Im-
munohistochemistry of lung tumor sections from DTRS mice for
CD3 antibody showing disappearance of T cells after 1 week of
DOX withdrawal. Hematoxylin (blue) was used as a counterstain
for immunohistochemistry.
Figure W14. Loss of cell differentiation during tumor regression. (A) Immunohistochemistry of lung tumor sections from DTRS mice with
pro–SP-C antibody showing loss of differentiation after DOX removal. Pictures shown at the bottom are the higher-magnification views
of the insets. Asterisks mark pro–SP-C–expressing alveolar type II cells. Hematoxylin (blue) was used as a counterstain for immuno-
histochemistry. (B) Dual immunofluorescence staining of the lung tumor sections for indicated markers confirming the upper results.
Nuclei were counterstained with DAPI (blue).
Figure W15. Down-regulation of oncogenic C-RAF by DOX withdrawal in induced lung tumors leads to cell cycle arrest. (A) Sections of
lungs from DTRS mice treated with DOX for 8 months and after removal of the inducer for 1 day, 3 days, 1 week, or 2 weeks were
immunostained for Ki67 (brown). Hematoxylin (blue) was used as a counterstain for immunohistochemistry. (B) Quantitation of Ki67
immunohistochemistry. At least 10 different random tumor areas were counted for each mouse. Error bars are SEM from four differ-
ent mice for each category. *Statistically significant (P < .05). (C) Immunoblot analysis of lung tumor protein lysates from induced or
DOX-removed DTRS mice for cyclin D2. Actin was used as a loading control.
Figure W16. Deinduction of oncogenic C-RAF in lung tumors of DTRS mice leads to reduction in senescence-associated markers. (A)
Immunohistochemical analysis of lung tumor sections for the indicated proteins. Hematoxylin (blue) was used as a counterstain for
immunohistochemistry. For p53 staining, tumor section of a xenograph generated by subcutaneous injection of mouse MLE-15 NSCLC
was used as a positive control. For HP-1γ, p16, and p21 immunohistochemistry, lung tumor sections from K-rasLA2 mouse were used as
a positive control. Circled regions represent tumor cells with nuclear p53 staining. (B) Immunoblot analysis of lung tumor lysates from
induced or DOX-removed DTRS mice for indicated markers. MLE-15 D indicates MLE-15 cells treated with doxorubicin hydrochloride;
MLE-15 H, MLE-15 cells treated with cycloheximide.
Figure W17. DOX withdrawal from oncogenic C-RAF–driven lung tumors does not lead to increased apoptosis. (A) Sections of lung
tumors from DTRS mice for the indicated DOX schedules were assayed for apoptotic cells using the TdT-mediated dUTP nick end labeling
(TUNEL) procedure. Examples of TUNEL-positive cells are indicated by red arrows. (B) Quantification of TUNEL-positive cells/high-power
field (HPF). Error bars are SEM from three different mice for each category.
Figure W18. Absence of apoptosis in oncogenic C-RAF–driven lung tumors after deinduction. (A) Analysis of genomic DNA fragmen-
tation in induced lung tumors removed from DOX for the indicated time points. About 1.5 μg of DNA was separated by electrophoresis
on a 2% agarose gel. A 100-bp marker was used for determining the size of the DNA fragments. MLE-15 cells that were treated either
with doxorubicin hydrochloride (MLE-15 D) or cycloheximide (MLE-15 H) and show DNA fragmentation compared to parental MLE-15
cells were used as positive controls. (B) Cleavage of caspase-3 and PARP expression in control and deinduced lung tumor lysates by
Western blot analysis. Actin was used as a loading control.
Figure W19. Oncogenic C-RAF–driven lung tumors display lower
autophagic capacity than their surrounding nontumor regions.
Immunohistochemical analysis of lung tumor sections from DOX-
induced and deinduced DTRS mice for LC-3. Hematoxylin (blue)
was used as a counterstain for immunohistochemistry.
Figure W20. Inhibition of mTOR signaling in regressing lung tumors
does not correlate with AMPK activation. Immunoblot analysis of
lung tumor lysates from induced or DOX-removed DTRS mice for
the indicated markers. Actin was used as a loading control.
